HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice
- 1 December 2005
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (12), 2642-2647
- https://doi.org/10.1161/01.atv.0000192018.90021.c0
Abstract
Objective— HIV combination therapy using protease inhibitors is associated with elevated plasma levels of atherogenic lipoproteins and increased risk for atherosclerosis. We investigated whether the HIV entry inhibitor TAK-779 affects lipoprotein levels and atherogenesis in low-density lipoprotein receptor-deficient mice. TAK-779 is an antagonist for the chemokine receptors CCR5 and CXCR3, which are expressed on leukocytes, especially T-helper 1 cells, and these receptors may be involved in recruitment of these cells to atherosclerotic plaques.Keywords
This publication has 25 references indexed in Scilit:
- Cardio- and cerebrovascular events in HIV-infected personsAIDS, 2004
- Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in MiceCirculation Research, 2004
- Induction of a Regulatory T Cell Type 1 Response Reduces the Development of Atherosclerosis in Apolipoprotein E–Knockout MiceCirculation, 2003
- T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesionsProceedings of the National Academy of Sciences, 2003
- Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 −2518 G/G genotype in CAD patientsAtherosclerosis, 2001
- Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarctionGenes & Immunity, 2001
- Human Vascular Smooth Muscle Cells Possess Functional CCR5Published by Elsevier ,2000
- The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.JCI Insight, 1998
- Antiretroviral effect of zidovudine–didanosine combination on blood and lymph nodesAIDS, 1997
- The role of a mutant CCR5 allele in HIV–1 transmission and disease progressionNature Medicine, 1996